National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

TThe annual increase in the prevalence of type 2 diabetes mellitus emphasizes the relevance of the search for new treatment options, along with necessity for regular review of proven therapeutic solutions. Today, dipeptidyl peptidase-4 inhibitors (DPP-4i, gliptins) are effective and safe hypoglycemi...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Shestakova, G. R. Vagapova, O. K. Vikulova, G. R. Galstyan, T. Yu. Demidova, E. N. Dudinskaya, T. P. Kiseleva, A. M. Mkrtumyan, N. A. Petunina, O. N. Tkacheva, V. V. Fadeev, Y. S. Khalimov, E. A. Shestakova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2023-12-01
Series:	Сахарный диабет
Subjects:	dpp-4 inhibitors type 2 diabetes mellitus gliptins sitagliptin
Online Access:	https://www.dia-endojournals.ru/jour/article/view/13110
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
by: D. V. Kurkin, et al.
Published: (2023-02-01)

Cerebroprotective effect of sitagliptin and aminoguanidine combination in disorders of cerebral circulation
by: D. V. Kurkin, et al.
Published: (2023-08-01)

The Diketopyrrolopyrrole (DPP) Core as a Gel-Forming Material: Current Status and Untapped Potential
by: Abelardo Sánchez-Oliva, et al.
Published: (2025-02-01)

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
by: Nina A. Petunina, et al.
Published: (2016-12-01)

Dipeptidyl peptidase-4 enzyme inhibition and its impacts on hepatic preneoplasia: a new avenue for liver cancer management
by: Hebatollah E. Eitah, et al.
Published: (2025-07-01)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
by: Elena V. Biryukova
Published: (2019-12-01)

DPP8 and DPP9 promote tubular epithelial cell ferroptosis in acute kidney injury
by: Kexin Guan, et al.
Published: (2025-07-01)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01)

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
by: Marwa Abdeltawab Mohammed, et al.
Published: (2024-12-01)

Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment
by: Dina Azkiyah, et al.
Published: (2025-05-01)

Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
by: Basavana Goudra, et al.
Published: (2024-12-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

DPP4 rs17574 polymorphism and elevated DPP4 levels linked to fatty liver in subclinical atherosclerosis: GEA study findings
by: Gilberto Vargas-Alarcón, et al.
Published: (2025-04-01)

ASSESSMENT OF SITAGLIPTIN INFLUENCE ON ARTERIAL WALL STIFFNESS, RENAL FUNCTION AND RENAL CIRCULATION IN CARDIOVSCULAR PATIENTS WITH DECOMPENSATED TYPE 2 DIABETES
by: E. V. Oskola, et al.
Published: (2015-03-01)

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS
by: Martina Kurnia Rohmah
Published: (2018-03-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach
by: Delower Hossain, et al.
Published: (2025-07-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Preparation and Encapsulation of DPP-IV Inhibitory Peptides: Challenges and Strategies for Functional Food Development
by: Rui Zhao, et al.
Published: (2025-04-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)

DPP-IV Inhibition by Solubilized Elastin Peptides from Yellowtail Bulbus Arteriosus Suppresses Ultraviolet-B-Induced Photoaging in Hairless Mice
by: Kumiko Takemori, et al.
Published: (2024-12-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

Navigating CDC recognition for the National DPP in socially vulnerable communities: barriers, facilitators, and recommendations
by: Taynara Formagini, et al.
Published: (2025-03-01)

Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01)

The role of DPP6 dysregulation in neuropathology: from synaptic regulation to disease mechanisms
by: Xuan-Yan Ding, et al.
Published: (2025-03-01)

Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma
by: Dongyuan Su, et al.
Published: (2025-07-01)

Taurine as a supplement for treating type II diabetes mellitus with metformin and DPP4 inhibitor
by: Tianyichen Xiao, et al.
Published: (2025-05-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

3-(3-Azabicyclo[2, 2, 1]heptan-2-yl)-1,2,4-oxadiazoles as Novel Potent DPP-4 Inhibitors to Treat T2DM
by: Tatiana V. Zinevich, et al.
Published: (2025-04-01)

Nutritional value, antibacterial activity, ACE and DPP IV inhibitory of red pomegranate seeds protein and peptides
by: Zahra Akbarbaglu, et al.
Published: (2025-03-01)

Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies
by: Jérémie Decalf, et al.
Published: (2016-04-01)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
by: Marina Vladimirovna Shestakova
Published: (2011-12-01)

Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
by: Alina Y. Babenko, et al.
Published: (2018-09-01)

Enhanced meropenem activity and stability following load in Polyvinyl alcohol nanofiber scaffolds with sitagliptin as quorum sensing inhibitor on Pseudomonas aeruginosa
by: Abdelrahman A. Mohsen, et al.
Published: (2025-08-01)

The Impact of Sitagliptin on Sodium Valproate-Induced Autism in a Mouse Model
by: Ahmed Sudan Abbas, et al.
Published: (2024-09-01)

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01)

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
by: Long He, et al.
Published: (2025-02-01)

Aktivitas Penghambatan Dipeptidyl peptidase-4 (DPP-4) dan Skrining Fitokimia Ekstrak Buah Api-api (Avicennia marina)
by: Dwi Hadi Setya Palupi, et al.
Published: (2025-06-01)